Русский
Sunitinib (sutent) In The First Line Of Metastatic Renal Cell Carcinoma
S.L. Gutorov, E.I. Borisova, M.R. Lichinicer
Sunitinib (Sutent) in the first line of metastatic renal cell carcinoma
The results of clinical studies on the sunitinib efficacy in the treatment of metastatic renal cell carcinoma are presented. It is shown that as the first-line treatment sunitinib administration compared with interferon alfa significantly increases the frequency of achieving objective response (47 versus 12%), more than 2-fold increased median time to progression (11 versus 4 months). Effective treatment by sunitinib leads to an increase in median overall survival of patients at 26.4 months. The high therapeutic efficacy and acceptable range of side effects allow recommending sunitinib as the drug of choice in first-line treatment of disseminated clear-cell renal carcinoma.
The results of clinical studies on the sunitinib efficacy in the treatment of metastatic renal cell carcinoma are presented. It is shown that as the first-line treatment sunitinib administration compared with interferon alfa significantly increases the frequency of achieving objective response (47 versus 12%), more than 2-fold increased median time to progression (11 versus 4 months). Effective treatment by sunitinib leads to an increase in median overall survival of patients at 26.4 months. The high therapeutic efficacy and acceptable range of side effects allow recommending sunitinib as the drug of choice in first-line treatment of disseminated clear-cell renal carcinoma.
Similar Articles
